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Summary  32 
The Xpert MTB/RIF assay detects Mycobacterium tuberculosis in unprocessed or 33 
NALC/NaOH- decontaminated sputum. The effect of repeated NALC/NaOH-34 
decontamination on several Xpert performance parameters was assessed in this study. A 35 
second NALC/NaOH-decontamination had no effect on the binary Xpert-outcome but 36 
increased the value for the quantitative readout (CTmin). Repeated decontamination was 37 
not associated with PCR-inhibition or invalid results.  The CTmin of M.tb positive samples 38 
was higher in inhibited Xpert runs. Our data indicate that NALC/NaOH-decontamination 39 
has an effect on the performance of the Xpert assay, and that CTmin readouts of 40 
decontaminated sputum samples should be interpreted with caution. 41 
 42 
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Introduction 46 
The Xpert MTB/RIF assay (Xpert) is a fully automated PCR test [1], which has been 47 
endorsed by WHO for the rapid detection of Mycobacterium tuberculosis (M.tb) in 48 
sputum samples. As previously published, fresh unprocessed sputum as well as 49 
NALC/NaOH-decontaminated, concentrated sputum pellets can be used for Xpert testing 50 
without effecting the assay´s sensitivity to detect M.tb [2]. While Xpert testing is usually 51 
performed on unprocessed sputum samples in most clinical settings, decontaminated 52 
sputum samples are often used in the context of research and Xpert evaluation studies [3-53 
5]. It is not unusual for sputum samples to require repeated decontamination due to 54 
bacterial overgrowth in culture. The impact of NALC/NaOH-decontamination on Xpert´s 55 
capacity to detect M.tb are scarce apart from the study by Boehme et el. [2].  Furthermore, 56 
only a few studies have analysed the inhibition of Xpert in sputum and extrapulmonary 57 
samples [6-9]. Blakemore and colleagues showed that inhibition of the Xpert assay 58 
resulted in an increased CTmin for M.tb- positive samples and poorer correlation with the 59 
quantitative readouts of the standard methods [10]. Although the typical inhibitors are 60 
usually specific to sample type and related characteristics, insoluble calcium-phosphate 61 
crystals, formed during the NALC/NaOH-processing, were also reported to inhibit DNA 62 
amplification [11]. In this study we analysed the effect of repeated decontamination on 63 
critical performance parameters of Xpert such as detection of M.tb and PCR-inhibition.   64 
 65 
Results and Discussion 66 
We used serial sputum samples from initially smear positive patients enrolled into a 67 
phase III TB treatment trial (ClinicalTrials.gov: NCT00864383) in Mbeya, Tanzania. 68 
Comprehensive information on ethical aspects, study design and laboratory methods have 69 
been published elsewhere [3, 12].  Briefly, after the samples were homogenized and 70 
decontaminated, the resulting pellet was processed for smear microscopy and culture 71 
methods and the residual was stored at 4°C.  If the first culture result was lost due to 72 
contamination within the first ten days after inoculation the sputum samples were 73 
decontaminated for a second time.   74 
A total of 1134 once or twice decontaminated sputum samples from 90 patients were 75 
stored at -80°C until Xpert testing (GeneXpert Dx version 2.1 and 4.0). 97.62% of all 76 
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samples (1107/1134) had a final Xpert result (Figure 1), and 38.8% (440/1134) of 77 
samples were decontaminated twice -out of which seven had an invalid result- with a 78 
non-significant trend (p= 0.063) towards a higher proportion of repeated decontamination 79 
for samples from the later study time points.  80 
The Xpert test includes a sample processing control (SPC), to confirm adequate 81 
processing and to detect the presence of inhibitors. A negative result for SPC indicates an 82 
invalid test in M.tb-negative samples. In M.tb-positive samples a PCR-run with a CT 83 
value of >34 for the SPC is considered as inhibited [10]. As shown before by Blakemore 84 
at al. [10], we confirmed in this study that in Xpert-positive samples with a CT>34 for 85 
SPC the readout for minimal cycle threshold (CTmin) was significantly increased (p 86 
<0.001) compared to samples with a CT<34 for the SPC (data not shown).   We further 87 
questioned whether Xpert-inhibition could be caused by NALC/NaOH-decontamination 88 
and found no data to support this idea.  In fact, the risk for an invalid or inhibited Xpert 89 
runs was even reduced by 32% and 18%, respectively, after repeated decontamination. 90 
Although this observation was not statistically significant in our study (Table 1), it is in 91 
line with other reports, indicating that additional samples processing steps such as sample 92 
washing, centrifugation or filtration may reduce inhibition of Xpert [6-8]. 93 
The GeneXpert software reports qualitative test results as well as semi quantitative 94 
readouts based on the CTmin determined by one out of five probes specific for M. 95 
tuberculosis complex becoming positive first. In this study we were investigating the 96 
effect of NALC/NaOH-decontamination on the qualitative and quantitative Xpert 97 
MTB/RIF result. The analysis of the 1107 samples with a final Xpert result showed that 98 
there was no difference in the binary outcome, TB positive or negative, between samples 99 
that had been decontaminated once or twice (Table 1).  This is consistent with recent 100 
findings, indicating that the assay´s sensitivity for M. tb was not affected regardless 101 
whether fresh or NALC/NaOH-decontaminated sputa were used [2]. We expand this 102 
observation to find out whether repeated decontamination had any effect on the bacterial 103 
load measured by the CTmin. Our analysis of 880 samples with a M.tb-positive Xpert result 104 
revealed that duplicate decontamination did have a significant effect on the reported 105 
bacterial load of a sample, expressed as the number of cycle thresholds (CTmin) and the 106 
semi-quantitative readouts (Table 1). The overall median for CTmin in twice versus once 107 
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decontaminated samples was significantly higher, 23.8 versus 21.5 (p<0.001), and this 108 
might be interpreted as a lower bacterial load. Further, after adjusting for week after 109 
treatment initiation in the regression model, the risk for the detection of “high” bacterial 110 
burden measured by Xpert was reduced by 42% (RR= 0.58, 95%CI: 0.40 to 0.86, p= 111 
0.007) for twice contaminated samples, whereas the risk was increased by 50% (RR= 112 
1.50, 95%CI: 1.10 to 2.04, p= 0.010) for detecting a “very low” bacterial burden. The 113 
lower risk for detection of “high” amount of DNA in connection with a greater risk for 114 
detection of “very low” amount of bacterial DNA for twice decontaminated samples 115 
suggest, that the amount of detectable DNA is reduced by a second decontamination step. 116 
Loss of apparent bacterial load following NALC/NaOH- decontamination is well 117 
recognized for a culture end point [13-14]. Unlike other PCR-assays [14], the Xpert assay 118 
was designed to detect only DNA that is associated with viable mycobacteria, which is 119 
achieved by an integrated mesh and washing step [1]. Yet, we have shown that DNA 120 
linked to non-viable bacilli is also detected by Xpert [3]. The data of this study suggest, 121 
that the second decontamination appears to render some mycobacterial DNA 122 
undetectable by Xpert in these samples.  Although we were not comparing fresh sputum 123 
results with data of single decontaminated samples, it is likely that a similar effect of 124 
NALC/NaOH decontamination will be detectable in such comparison. This, however, 125 
needs confirmation by further studies. 126 
In addition to the previous publication by Devonshire et al. [15], which showed that there 127 
is a huge variability among Xpert CTmin data generated from different GeneXpert 128 
instruments, these data provide additional evidence that Xpert CTmin or semi-quantitative 129 
readouts should be used with great caution, when they are used for allocation into 130 
different arms or comparison of treatments within clinical trials or for judgments 131 
regarding disease progression, infectiousness or response to anti-TB treatment within 132 
clinical settings. Uncritical application of NALC/NaOH-decontamination in the 133 
laboratory or unawareness about these procedures among clinicians and scientist might 134 
lead to misinterpretation of quantitative Xpert data and underestimation of mycobacterial 135 
load.  These data further suggest that twice decontaminated sputum samples should be 136 
excluded from the interpretation of quantitative Xpert results [3-5]. Future evaluation 137 
studies of Xpert or up-coming newer versions of this test should include an assessment of 138 
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the effect of different sputum processing steps on the relevant diagnostic performance 139 
parameters of this assay. 140 
141 
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 TABLE 1: The effect of repeated NALC/NaOH-decontamination on Xpert results 199 
 200 
  Re- Decontamination        
  Yes No RR* 95%CI for RR* p-value* 
Xpert positive % , n=1107
†
 76.7 (332/433) 81.3 (548/674) 0.98 0.92 to 1.05 0.594 
Xpert semi-quantitative result, n=880
‡
      
high %  7.8 (26/332) 14.8 (81/548) 0.58 0.40 to 0.86 0.007 
medium % 30.7 (102/332) 40.3 (221/548) 0.80 0.65 to 0.99 0.037 
low % 37.7(125/332) 30.7(168/548) 1.22 0.96 to 1.54 0.099 
very low % 23.8 (79/332) 14.2 (78/548) 1.50 1.10 to 2.04 0.010 
Xpert CTmin (overall median), n=880
‡
 23.8  21.5  1.07 1.04 to 1.11 <0.001 
Invalid PCR run (SPC0= 0) %, n=1134
§
 4.1 (18/440) 6.1 (42/694) 0.68 0.36 to 1.29 0.237 
PCR inhibited (SPC > 34), %, n=1071
||
 8.5 (36/422) 10.6 (69/649) 0.82 0.57 to 1.18 0.283 
      
RR: risk ratio, 95%CI: 95% confidence interval, Xpert: Xpert MTB/RIF assay, SPC: sample processing control, PCR: polymerase chain reaction 
  
* Adjusted for week after treatment initiation 
† 1107 samples with a valid Xpert result were included in the analysis 
‡ 880 samples with an M. tuberculosis positive Xpert result were included in the analysis 
§ Total amount of 1134 samples from 90 smear positive TB patients were included in this analysis 
|| 1071 samples with a positive result for SPC (SPC ≠ 0) were included in this analysis 
 
 201 
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FIGURE 1 203 
Title: Sample flow chart  204 
Legend: The sample chart is reflecting all 1134 samples which were included in the study 205 
and their distribution to different subgroups for analysis. 206 
 207 
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